Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene cileleucel in relapsed or refractory indolent non-Hodgkin lymphoma (XUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncology. 2022;1:91–103. https://doi.org/10.10106/S1470-2045(21)00591-X.

Article  Google Scholar 

•• Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EMBT (JACIE). Haematologica. 2020;105:297–316. https://doi.org/10.3324/haematol.2019.229781. (This editorial highlights the practical recommendations for CAR-T cell therapy patients, including how to manage and treat CRS and ICANS.)

Article  PubMed  PubMed Central  Google Scholar 

Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-Care Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. Clin Oncol. 2022;27:3119–28. https://doi.org/10.1200/JCO.19.02104.

Article  Google Scholar 

Locke Frederick L, Miklos David B, Jacobson Caron A, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54. https://doi.org/10.1056/NEJMoa2116133.

Article  CAS  PubMed  Google Scholar 

Neelapu SS, Locke FL, Lekakis LJ, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med. 2017;26:2531–44. https://doi.org/10.1056/NEJMoa1707447.

Article  Google Scholar 

Spiegel JY, Dahiya S, Jain MD, et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021;13:1832–5. https://doi.org/10.1182/blood.2020006245.

Article  CAS  Google Scholar 

• Lee Daniel W, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Guideline. 2019;25:625–38. https://doi.org/10.1016/j.bbmt.2018.12.758. (These are guidelines for grading and treating CRS and ICANs.)

Article  CAS  Google Scholar 

Cassidy, Sorcha; Webster, Rachel; and D. Phil. 2020. CAR T-Cell Therapy in non-Hodgkin’s lymphoma: where do we go from here? Cell and gene. https://www.cellandgene.com/doc/car-t-cell-therapy-in-non-hodgkin-s-lymphoma-where-do-we-from-here-0001

O Oluwole Olalekan Krimo Bouabdallah Javier Munoz et al Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma Bri J Haematol 2021;194:690 700 https://doi.org/10.1111/bjh.175257

Neelapu Sattva S, Summala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nature. 2018;15:47–62. https://doi.org/10.1038/nrclinonc.2017.148.

Article  CAS  Google Scholar 

Pennisi M, Jain T, Santomasso B, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4:675–86. https://doi.org/10.1182/bloodadvances.2019000952.

Article  CAS  Google Scholar 

Hong Ruimin Hu, Yongxian, and Huang He. Biomarkers for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: prospects for personalized management and prognostic prediction. Frontiers in Immunology. 2021; 12. https://doi.org/10.3389/fimmu.2021.627764.

Morris, Emma; Neelapu, Sattva; Giavridis, Theodoros; and Michel Sadelain. 2021. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Revs Immunolhttps://doi.org/10.1038/s41577-021-00547-6

Greenbam U, Strati P, Saliba RM, et al. CRP and ferritin in addition to the EASIX score predict CAR-T related toxicity. Blood Adv. 2021;5(14):2799–806. https://doi.org/10.1182/bloodadvances.2021004575.

Article  CAS  Google Scholar 

Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136:925–35. https://doi.org/10.1182/blood.2019004000.

Article  PubMed  PubMed Central  Google Scholar 

• Lee, Daniel; Santomasso, Bianca; Locke, Frederick; et. Al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Transplantation and Cellular Therapy. 2018. Doi: https://doi.org/10.1016/j.bbmt.2018.12.758. (These are Guidelines for grading and treating CRS and ICANs.)

Si S, Teachey D. Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag. 2020;16:705–14.

CAS  PubMed  PubMed Central  Google Scholar 

Ahmed S, Furquan F, Strati P, et al. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). J Clin Oncol. 2020;38:8057. https://doi.org/10.1200/JCO.2020.38.15_suppl.8057.

Article  Google Scholar 

RD Sandler RS Tattersall H Schoemans et al Diagnosis and management of HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice with EBMT centers on behalf of the Autoimmune Disease Working Party (ADWP) and Transplant Complications Working Party (TCWP) Front Immunol 2022 11https://doi.org/10.3389/fimmu.2020.00524

Belin C, Devic P, Antoine C. Description of neurotoxicity in a series of patients treated with CAR-T cell therapy. Scientific Reports. 10. https://doi.org/10.1038/s41598-020-76055-9.

Chavez J, Jain M, Kharfan-Dabaja M. Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: a comprehensive review of emerging grading models. Hematol Oncol Stem Cell Ther. 2020;13:1–6. https://doi.org/10.1016/j.hemonc.2019.05.005.

Article  CAS  PubMed  Google Scholar 

Ibrahim U, Osman K. Cytopenias following CAR-T cell therapy – a single center experience. Biol Blood Marrow Transplant. 2020;26:S260. https://doi.org/10.1016/j.bbmt.2019.12.422.

Article  Google Scholar 

Stewart AG, Henden AS. Infectious complications of CAR T-cell therapy: a clinical update. Ther Adv Infect Dis. 2021;8:1–11. https://doi.org/10.1177//20499361211036773.

Article  CAS  Google Scholar 

Bachanova V, et al. Chimeric antigen receptor T cell therapy during the COVID- 19 pandemic. Biol Blood Marrow Transplant. 2020;7:1239–46. https://doi.org/10.1016/j.bbmt.2020.04.008.

Article  CAS  Google Scholar 

• Mushtaq MU, Shahzad M, Chaudhary SG, et al. Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients. Transplant Cell Therapy. 2021;27:796e1–7. (This study looked at HSCT patients and CAR-T cell patients who had COVID, the complications they experienced, and how they were treated •)

Article  Google Scholar 

Dulery R, Lamure S, Heuso T, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96:934–44. https://doi.org/10.1002/ajh.26209.

Article  CAS  PubMed  PubMed Central  Google Scholar 

N Agrawal R Singh SK Sharma et al Outcomes of COVID-19 in hematopoietic stem cell transplant recipients: multicenter retrospective analysis Nature Publ Health Emerg Collect 2022;1–6https://doi.org/10.1007/s12288-021-01472-3

A Busca J Salmanton-Garcia L Pagano et al 2021 COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP Blood Advhttps://doi.org/10.1182/bloodadvances.2021005616

Vjenthria A, Gong IY, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systemic review and meta-analysis of 337 patients. Blood. 2020;136:2881–92. https://doi.org/10.1182/blood.2020008824.

Article  CAS  Google Scholar 

Spanjaart AM; Ljungman P, Miekle S, et. al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Disease Working Party and the European Hematology Association (EHA) Group. Leukemia. 2021;35:3585 -3588 https://doi.org/10.1038/s41375-021-01466-0

Abassi J. Prolonged SARS-CoV-2 Infection in a CAR T-cell therapy recipient. JAMA. 2021;10:924. https://doi.org/10.1001/jama.2021.2493.

Article  Google Scholar 

Corey L, Beyrer C, Rolland M, et al. SARS-CoV-2 Variants in patients with immunosuppression. NEJM. 2021;385:562–6. https://doi.org/10.1056/NEJMsb2104756.

Article  CAS  PubMed  Google Scholar 

Corti D, Purcell LA, Veesler D, et al. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184:3086–108. https://doi.org/10.1016/j.cell.2021.05.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Food and Drug Administration. Frequently Asked Questions on the Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab) for Pre-exposure Prophylaxis (PrEP) of COVID-19. February 24, 2022. https://www.fda.gov/medica/154703/download

Aydillo T, Gonzalez-Reiche AS, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. NEJM. 2020;383:2586–8. https://doi.org/10.1056/NEJMc2031670.

Article  CAS  PubMed  Google Scholar 

Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Investig. 2020;12:6656–67. https://doi.org/10.1172/JCI141777.

Article  Google Scholar 

Liebers N, Speer C, Dietrich S, et al. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood. 2021;139(1):142–7. https://doi.org/10.1182/blood.2021013445.

Article  CAS  Google Scholar 

• National Comprehensive Cancer Network (NCCN). 2022. COVID-19 resources and guidelines. https://www.nccn.org/covid-19. (These are guidelines for COVID-19 treatment in immunocompromised patients.)

Maneikis K, Sablauskas K, Kryzauskaite L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with hematological malignancies in Lithuania: a national prospective cohort study. Lancet Hematol. 2021;8:e583-592. https://doi.org/10.1016/S2352-3026(21)00169-1.

Article  Google Scholar 

Sharma A, Bhatt NS, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Hematol. 2021;8:185–93. https://doi.org/10.1016/S2352-3026(20)30429-4.

Article  Google Scholar 

•• Khawaja MD, Fareed; Chemaly MD, Roy F.; Dadwal MD, Sanjeet; et al. September 29, 2021. ASH-ASTCT COVID-19 Vaccination for HCT and CAR T cell recipients: Frequently Asked Questions. American Society of Hematology. https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell%20recipients (This article outlined the COVID-19 vaccination schedule for immunocompromised patients and vaccination timing in immunocompromised patients who received monoclonal antibodies for prevention or treatment of COVID-19.)

Sun C, Pleyer C, Wiestner A. COVID-19 vaccines for patients with haematological conditions. Lancet Haematology. 2021;8(5):e312–4. https://doi.org/10.1016/S2352-3026(21)00073-9.

Article  PubMed  Google Scholar 

Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–73. https://doi.org/10.1182/blood.2021011568.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Leukemia & Lymphoma Society (LLS). Study from the Leukemia & Lymphoma Sociate shows COVID-19 vaccine is safe but 25% of blood cancer patients do not produce detectable antibodies. 2022. https://www.lls.org/news/study-leukemia-lymphoma-society -shows-covid-19-vaccine-safe-25-blood-cancer-patients-do-not. (The Leukemia and Lymphoma Society has up-to-date guidelines for COVID-19 vaccinations for CAR-T cell recipients and their family members.)

Gentile I, Moriello N. COVID-19 prophylaxis in immunosuppressed patients: beyond vaccination. PLos Med. 2022;19(1):e1003917. https://doi.org/10.1371/journal.pmed.1003917.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma N, Reagan PM, Liesveld JL. Cytopenia after CAR-T cell therapy-a brief review of a complex problems. Cancers. 2022;14:1501. https://doi.org/10.3390/cancers14061501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobson, C; Locke, FL; Ghobaid, A; Munoz, J; et. al. Hematology disease topics and pathways: biological therapies, adults, lymphomas, non-Hodgkin lymphoma, B cell lymphoma, chimeric antigen receptor (CAR)-T cell therapies, diseases, immune mechanism, therapies, lymphoid malignancies, biological processes, study population. ASH oral posters and abstracts (2021). https://ash.confex.com/ash/2021/webprogram/Paper14807&html

Locke FL, Ghobadi A, Munoz J, Neelapu SS, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicenter, phase 1–2 trial. Lancet Oncol. 2019;20:31–42. https://doi.org/10.1016/S1470-204(18)30864-7.

Article  CAS  PubMed  Google Scholar